Severe graft-versus-host disease is a major barrier for non-T-cell-depleted haploidentical
stem cell transplantation. There is no consensus on the optimal graft-versus-host disease …

We report a modified post-transplant cyclophosphamide (PT-CY) regimen, for
unmanipulated haploidentical marrow transplants, in 150 patients with acute myeloid …

Large series of patients with acute myelogenous leukemia (AML) after ex vivo T cell-
depleted (TCD) allogeneic hematopoietic stem cell transplantation (allo-HSCT) have not …

Allo-HSCT remains the standard of care for high-risk AML. Increased access to transplant,
reduced toxicity and relapse are improving patient outcomes. Further research is needed to …

The integration of antithymocyte globulin (ATG) into therapy has significantly reduced the
incidence of graft-versus-host disease (GVHD) and is being actively used in allogeneic …

The clinical outcome of primary refractory (PRF) AML patients is poor and only a minor
proportion of patients is rescued by allogenic hematopoietic stem cell transplantation …

Background Both mismatched unrelated donor (MMUD) and haploidentical (haplo)
transplantation are valid options in patients with high‐risk acute lymphoblastic leukemia …

We evaluated the efficacy of hematopoietic stem cell transplantation (HSCT) using reduced
intensity (RI) vs. myeloablative (MA) conditioning for patients with acute myeloid leukemia …

We retrospectively compared the antileukemic effects of chemotherapy alone and
chemotherapy followed by modified donor lymphocyte infusion (DLI) in 82 patients with …

For patients with acute myeloid leukemia (AML) in complete remission without an
acceptable HLA donor, the autologous hematopoietic stem cell transplantation (AHSCT) …